Table 1. Age restrictions and indications for selected respiratory drug classes.
| Compound class | Compound | ATC-code* | Age restriction | Approved indication(s) |
| Inhaled SABA | Salbutamol | R03AC02 | None | Asthma, chronic obstructive bronchitis, pulmonary emphysema with reversible obstruction, prophylaxis of allergic asthma and exercise-induced asthma |
| Fenoterol | R03AC04 | ≥4 years | Asthma, chronic obstructive bronchitis, pulmonary emphysema with reversible obstruction, prophylaxis of allergic asthma and exercise-induced asthma | |
| Terbutaline | R03AC03 | ≥5 years | Asthma, chronic obstructive bronchitis, pulmonary emphysema with reversible obstruction | |
| Inhaled SABA combination | Ipratropium/Fenoterol (fixed combination) | R03AK03 | None | Asthma, COPD |
| Reproterol/CGA (fixed combination) | R03AK05 | None | Asthma | |
| Inhaled LABA | Salmeterol | R03AC12 | ≥4 years | Asthma, COPD |
| Formoterol | R03AC13 | ≥6 years | Asthma, COPD | |
| Inhaled LABA/ICS | Salmeterol/Fluticasone (fixed combination) | R03AK06 | ≥4 years | Asthma, COPD |
| Formoterol/Beclomethasone (fixed combination) | R03AK27 | ≥6 years | Asthma | |
| Formoterol/Budesonide (fixed combination) | R03AK28 | ≥6 years | Asthma, COPD | |
| Inhaled SAMA | Ipratropium | R03BB01 | None | Asthma, COPD |
| Inhaled LAMA | Tiotropium | R03BB04 | ≥18 years | COPD |
| ICS | Budesonide | R03BA02 | None | Respiratory diseases (inclusive asthma and COPD) requiring ICS |
| Beclomethasone | R03BA01 | None | Respiratory diseases (inclusive asthma and COPD) requiring ICS | |
| Fluticasone | R03BA05 | ≥4 years | Asthma, COPD | |
| Ciclesonide | R03BA08 | ≥12 years | Asthma | |
| Oral B2A | Salbutamol | R03CC02 | None | Obstructive respiratory diseases, asthma, COPD, pulmonary emphysema |
| Terbutaline | R03CC03 | None | Obstructive respiratory diseases, asthma, COPD, pulmonary emphysema | |
| Tulobuterol | R03CC11 | ≥1year | Obstructive respiratory diseases, asthma, COPD, pulmonary emphysema | |
| Clenbuterol | R03CC13 | None | Asthma, asthmatic bronchitis, chronic bronchitis, pulmonary emphysema | |
| Oral B2A combinations | Clenbuterol/Ambroxol | R03CC63 | None | Acute and chronic bronchitis, pulmonary emphysema, asthma |
| Others | Theophylline | R03DA04 | ≥1year | Asthma, COPD |
| Montelukast | R03DC03 | ≥1 year | Asthma, prophylaxis of exercise-induced asthma | |
| Cromoglicic acid | R03BC01 | ≥2 years | Asthma |
SABA: Short-acting beta-2-agonist, CGA: Cromoglicic acid, LABA: Long-acting beta-2-agonist, ICS: Inhaled corticosteroid, SAMA: Short-acting muscarinic antagonist, LAMA: Long-acting muscarinic antagonist, B2A: Beta-2-agonist. (*German version available at http://www.dimdi.de/static/de/amg/atcddd/index.htm).